[Holmium laser enucleation of the prostate (HoLEP) in XXXX with continuous oral anticoagulation: first reported cases in Japan].

@entity1 @entity1697 @entity190 @entity1067 @entity1372
@entity1697 ( @entity1697 ) has been considered as a strict contraindication to transurethral resection of the prostate (TURP). In recent years, some studies have shown that holmium laser enucleation of the prostate (HoLEP) has less @entity190 compared to TURP. Thus we have performed HoLEP in @entity1 with @entity1067 ( @entity1067 ) under continuous @entity1697 from September 2009, and herein we report our first nine cases. @entity1 received HoLEP by a single surgeon at our institution. HoLEP was performed successfully in all @entity1 . The mean times to complete enucleation and morcellation were 48.2 and 5.1 minutes, respectively. The mean tissue weight of enucleation was 37 grams. The mean hemoglobin and @entity1372 loss after HoLEP were 1.7 g/dl and 1.3 mEq/L, respectively, and the catheterization time was 1.6 days. Blood transfusion, clot retention or transurethral resection syndrome were not observed in any cases. HoLEP has excellent hemostatic properties, and is a safe and effective procedure for @entity1 with symptomatic @entity1067 under the condition of continuous @entity1697 .
